Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics (Nasdaq: KROS) reported first quarter 2026 results and a key pipeline update. Net loss was $23.7 million, versus net income of $148.5 million a year earlier, mainly reflecting 2025 Takeda license revenue and lower research and development activity.
R&D expenses fell to $16.1 million from $48.7 million, and G&A expenses were $10.1 million versus $10.5 million. Cash and cash equivalents were $281.5 million, expected to fund operations into the first half of 2028. Partner Takeda plans a Phase 3 trial of elritercept in anemia in myelofibrosis.
Keros Therapeutics (Nasdaq: KROS) entered an agreement on March 9, 2026, with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in ALS patients under the Healey ALS MyMatch program.
The collaboration will use biomarker-driven, personalized trial methods to match ALS subgroups to experimental therapies and to identify optimal populations for later-stage trials.
Keros Therapeutics (Nasdaq: KROS) presented additional Phase 1 clinical data for rinvatercept (KER-065) at the 2026 MDA Clinical & Scientific Conference on March 9, 2026. Findings in healthy volunteers showed tolerability, body composition changes, and proteomic evidence of target engagement guiding development for DMD and ALS.
Key takeaways: generally well-tolerated with no dose-limiting toxicities or serious adverse events; increases in muscle mass and bone mineral density; decreases in fat mass; proteomic signals consistent with activin/myostatin inhibition, anti-fibrotic and anti-inflammatory effects.
Keros (Nasdaq: KROS) reported fourth-quarter 2025 net loss of $23.5M and full-year 2025 net income of $87.0M, driven largely by revenue from a license agreement with Takeda. The company expects to start a Phase 2 trial of rinvatercept in DMD in Q2 2026 and to engage regulators on an ALS Phase 2 design in H2 2026. Cash and cash equivalents were $287.4M at year-end, with management saying this funding is expected to support operations into the first half of 2028.
Keros Therapeutics (Nasdaq: KROS) appointed Charles Newton to its Board of Directors, effective March 9, 2026, and announced that Carl Gordon, Ph.D., CFA, will step down as director effective the same date.
Mr. Newton joins with healthcare finance and capital markets experience, including service as CFO of Lyell through September 2025 and current board roles at Novavax and Coherus Oncology.
Keros Therapeutics (Nasdaq: KROS) announced that CEO Jasbir S. Seehra, Ph.D., will present at three healthcare conferences in late February and March 2026: Oppenheimer (Feb 25), TD Cowen (Mar 3) and Leerink Partners (Mar 10).
Each presentation format is listed (corporate presentation or fireside chat) and archived replays will be available on the company investor website for up to 90 days after each event.
Keros Therapeutics (Nasdaq: KROS) announced final results of its cash tender offer to repurchase up to 10,950,165 shares at $17.75 per share for an aggregate purchase price of approximately $194.4 million. The Tender Offer expired on November 18, 2025 and concludes the company’s previously announced $375 million capital return program.
Computershare reported 17,712,262 shares were validly tendered; Keros accepted 10,950,165 shares on a pro rata basis with a final proration factor of approximately 62.30%. The purchased shares represent about 35.91% of outstanding common stock as of November 18, 2025. Payment for accepted shares will be made promptly from the company’s cash and cash equivalents.
Keros Therapeutics (Nasdaq: KROS) announced preliminary results of a cash tender offer that expired on November 18, 2025 to repurchase up to 10,950,165 shares at $17.75 per share for an aggregate purchase price of approximately $194.4 million. The tender concludes the company’s $375 million capital return program.
Approximately 16,659,732 shares were validly tendered (plus 1,186,829 via guaranteed delivery). Keros expects to accept 10,950,165 shares on a pro rata basis, representing about 35.91% of outstanding common stock as of November 18, 2025. Final counts are subject to Depositary confirmation.
Keros Therapeutics (Nasdaq: KROS) reported third quarter 2025 results on November 5, 2025. The company posted a net loss of $7.3 million in Q3 2025 versus a net loss of $53.0 million in Q3 2024, driven largely by revenue recognized under its license agreement with Takeda and a shift of elritercept R&D costs to Takeda.
R&D expenses were $19.5 million in Q3 2025 versus $49.2 million a year earlier. G&A expenses were $10.1 million versus $9.8 million. Cash and cash equivalents totaled $693.5 million as of September 30, 2025. The board has determined to return $375.0 million of excess capital to stockholders; after that amount, management expects cash to fund operations into the first half of 2028. Takeda plans to advance elritercept into a Phase 3 first-line MDS trial, and Keros plans to initiate a Phase 2 trial of KER-065 in Duchenne muscular dystrophy.
Keros Therapeutics (Nasdaq: KROS) commenced a cash tender offer on Oct 20, 2025 to repurchase up to $194.4 million of its common stock at $17.75 per share, part of a previously announced $375 million capital return program. The company expects to fund the tender offer from existing cash and cash equivalents.
The offer is scheduled to expire at 5:00 p.m. ET on Nov 18, 2025, unless extended or terminated. The company and its board made no recommendation to shareholders; full terms are filed with the SEC.